Nektar Therapeutics (NKTR) Current Assets (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Current Assets of $589.0 million for Q1 2026, up 156.2% year-over-year from $229.9 million in Q1 2025, and up 121.22% quarter-over-quarter from $266.3 million in Q4 2025.
Nektar Therapeutics (NKTR) Current Assets (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $589.0 million for Q1 2026.
- In Q1 2026, Current Assets rose 156.2% year-over-year to $589.0 million; the TTM figure through Mar 2026 stood at $589.0 million (up 156.2% YoY), while the FY2025 annual figure was $266.3 million, up 1.9% from the prior year.
- Current Assets for Q1 2026 stood at $589.0 million, up from $266.3 million in the prior quarter.
- The five-year high for Current Assets was $733.5 million in Q1 2022, with the low at $186.6 million in Q2 2025.
- The 5-year median for Current Assets is $330.7 million (2023), against an average of $407.2 million.
- The sharpest annual moves came in 2023 and 2026: Current Assets sank 39.43% in 2023, then jumped 156.2% in 2026.
- Nektar Therapeutics' Current Assets stood at $546.0 million in 2022, then tumbled by 39.43% to $330.7 million in 2023, then dropped by 20.99% to $261.3 million in 2024, then increased by 1.9% to $266.3 million in 2025, then surged by 121.22% to $589.0 million in 2026.
- Business Quant data shows NKTR's Current Assets at $589.0 million in Q1 2026, $266.3 million in Q4 2025, and $281.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | 589.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 589.04 Mn |
| Dec 31, 2025 | 266.27 Mn |
| Sep 30, 2025 | 281.36 Mn |
| Jun 30, 2025 | 186.57 Mn |
| Mar 31, 2025 | 229.91 Mn |
| Dec 31, 2024 | 261.29 Mn |
| Sep 30, 2024 | 286.48 Mn |
| Jun 30, 2024 | 295.19 Mn |
| Mar 31, 2024 | 319.84 Mn |
| Dec 31, 2023 | 330.70 Mn |
| Sep 30, 2023 | 399.03 Mn |
| Jun 30, 2023 | 441.06 Mn |
| Mar 31, 2023 | 491.07 Mn |
| Dec 31, 2022 | 545.97 Mn |
| Sep 30, 2022 | 599.48 Mn |
| Jun 30, 2022 | 665.54 Mn |
| Mar 31, 2022 | 733.46 Mn |
| Dec 31, 2021 | 795.58 Mn |
| Sep 30, 2021 | 986.14 Mn |
| Jun 30, 2021 | 1.06 Bn |